Context Therapeutics (CNTX) News Today $1.63 -0.02 (-1.21%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Research Analysts Issue Forecasts for CNTX FY2024 EarningsNovember 13, 2024 | americanbankingnews.comPromising Preclinical Data and Strategic Trial Design Support Buy Rating for Context TherapeuticsNovember 12, 2024 | markets.businessinsider.comHC Wainwright Has Bearish Forecast for CNTX FY2024 EarningsContext Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Stock analysts at HC Wainwright dropped their FY2024 earnings per share (EPS) estimates for Context Therapeutics in a research report issued on Thursday, November 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will posNovember 11, 2024 | marketbeat.comContext Therapeutics: A Promising Investment in Innovative Oncology Therapies with Strong Financial PositionNovember 10, 2024 | markets.businessinsider.comContext Therapeutics (NASDAQ:CNTX) Issues Quarterly Earnings ResultsContext Therapeutics (NASDAQ:CNTX - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.22) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.11).November 9, 2024 | marketbeat.comContext Therapeutics Announces Q3 2024 Financial Results and Strategic AdvancesNovember 9, 2024 | msn.comContext Therapeutics Reports Third Quarter 2024 Operating and Financial ResultsNovember 6, 2024 | globenewswire.comContext Therapeutics to Engage Investors at November ConferencesOctober 26, 2024 | msn.comContext Therapeutics to Participate in Upcoming Investor Conferences in NovemberOctober 23, 2024 | globenewswire.comContext Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual MeetingOctober 16, 2024 | finance.yahoo.comContext Therapeutics Announces Poster Presentation at the Society for Immunotherapy of Cancer's (SITC) 39th Annual MeetingOctober 16, 2024 | globenewswire.comContext Therapeutics (NASDAQ:CNTX) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comNantahala Capital Management LLC Buys Shares of 1,935,484 Context Therapeutics Inc. (NASDAQ:CNTX)Nantahala Capital Management LLC purchased a new position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,935,484 shares of the company's stock, valuOctober 1, 2024 | marketbeat.comDriehaus Capital Management LLC Purchases Shares of 2,258,065 Context Therapeutics Inc. (NASDAQ:CNTX)Driehaus Capital Management LLC acquired a new position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 2,258,065 shares of the company'sSeptember 30, 2024 | marketbeat.comBlue Owl Capital Holdings LP Takes $10.35 Million Position in Context Therapeutics Inc. (NASDAQ:CNTX)Blue Owl Capital Holdings LP bought a new stake in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 5,161,290 shares of the company's stSeptember 28, 2024 | marketbeat.comPiper Sandler Keeps Their Buy Rating on Context Therapeutics (CNTX)September 27, 2024 | markets.businessinsider.comBioAtla and Context Therapeutics Forge Strategic Agreement for Cancer Treatment DevelopmentSeptember 26, 2024 | msn.comHC Wainwright Comments on Context Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:CNTX)Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities researchers at HC Wainwright reduced their Q3 2024 earnings estimates for Context Therapeutics in a research report issued on Monday, September 23rd. HC Wainwright analyst E. Bodnar now expects that the company will post earnings peSeptember 26, 2024 | marketbeat.comBuy Rating Affirmed for Context Therapeutics Amid Strategic Licensing and Promising TCE Portfolio ExpansionSeptember 25, 2024 | markets.businessinsider.comContext Therapeutics Inc. (NASDAQ:CNTX) Stock Position Lifted by Affinity Asset Advisors LLCAffinity Asset Advisors LLC increased its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 392.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,September 25, 2024 | marketbeat.comGreat Point Partners LLC Purchases Shares of 7,419,355 Context Therapeutics Inc. (NASDAQ:CNTX)Great Point Partners LLC acquired a new position in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 7,419,355 shares of the company's stock, valued at approximately $14,876,000. Context TherapeuticsSeptember 24, 2024 | marketbeat.comBioAtla Grants Exclusive, Worldwide License To Context Therapeutics To Develop BA3362September 23, 2024 | markets.businessinsider.comBioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging AntibodySeptember 23, 2024 | globenewswire.comContext Therapeutics Inc. (NASDAQ:CNTX) Stock Holdings Boosted by Ally Bridge Group NY LLCAlly Bridge Group NY LLC boosted its position in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 159.8% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,886,232 shares of the company's stock after purSeptember 23, 2024 | marketbeat.comPiper Sandler maintains Overweight rating on Context Therapeutics stockSeptember 19, 2024 | uk.investing.comPositive Outlook for Context Therapeutics’ CTIM-76 Based on ESMO 2024 Data and Buy Rating by Emily BodnarSeptember 16, 2024 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Context Therapeutics (CNTX)September 16, 2024 | markets.businessinsider.comWe Think Context Therapeutics (NASDAQ:CNTX) Can Afford To Drive Business GrowthSeptember 16, 2024 | finance.yahoo.comContext Therapeutics' (CNTX) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $6.00 target price on shares of Context Therapeutics in a research note on Monday.September 16, 2024 | marketbeat.comContext Therapeutics Strengthens Board with Key AppointmentsSeptember 6, 2024 | msn.comContext Therapeutics Appoints Dr. Karen Smith and Dr. Luke Walker to Board of DirectorsSeptember 4, 2024 | globenewswire.comShort Interest in Context Therapeutics Inc. (NASDAQ:CNTX) Decreases By 7.9%Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) was the target of a significant decline in short interest in August. As of August 15th, there was short interest totalling 1,860,000 shares, a decline of 7.9% from the July 31st total of 2,020,000 shares. Currently, 3.1% of the company's shares are short sold. Based on an average daily trading volume, of 242,600 shares, the days-to-cover ratio is presently 7.7 days.September 2, 2024 | marketbeat.comResearch Analysts Set Expectations for Context Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:CNTX)Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) - Equities research analysts at HC Wainwright upped their Q3 2024 earnings per share (EPS) estimates for Context Therapeutics in a research report issued to clients and investors on Thursday, August 8th. HC Wainwright analyst E. Bodnar now forAugust 12, 2024 | marketbeat.comBuy Rating Affirmed for Context Therapeutics Amid Strong Financials and Promising CLDN6-Targeting TherapiesAugust 11, 2024 | markets.businessinsider.comContext Therapeutics (NASDAQ:CNTX) Posts Earnings Results, Beats Expectations By $0.04 EPSContext Therapeutics (NASDAQ:CNTX - Get Free Report) released its quarterly earnings data on Wednesday. The company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.08) by $0.04.August 11, 2024 | marketbeat.comBuy Rating Affirmed for Context Therapeutics as CTIM-76 Shows Promise and Strategic Team Expands Ahead of Clinical TrialsAugust 9, 2024 | markets.businessinsider.comContext Therapeutics Inc.: Context Therapeutics Reports Second Quarter 2024 Operating and Financial ResultsAugust 9, 2024 | finanznachrichten.deContext Therapeutics Reports Second Quarter 2024 Operating and Financial ResultsAugust 7, 2024 | globenewswire.comContext Therapeutics Inc.'s (NASDAQ:CNTX) top owners are individual investors with 52% stake, while 30% is held by private equity firmsAugust 6, 2024 | finance.yahoo.comContext Therapeutics Appoints New Chief Medical Officer and VP of Clinical OperationsAugust 3, 2024 | msn.comContext Therapeutics Appoints Chief Medical Officer and Vice President of Clinical OperationsAugust 1, 2024 | globenewswire.comContext Therapeutics Inc. (NASDAQ:CNTX) Short Interest Up 99.1% in JuneContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) saw a large growth in short interest during the month of June. As of June 30th, there was short interest totalling 2,230,000 shares, a growth of 99.1% from the June 15th total of 1,120,000 shares. Based on an average daily volume of 703,800 shares, the short-interest ratio is presently 3.2 days. Currently, 3.4% of the shares of the company are sold short.July 12, 2024 | marketbeat.comContext Therapeutics' (CNTX) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Context Therapeutics in a research report on Wednesday.July 10, 2024 | marketbeat.comContext Therapeutics Acquires Phase 1-ready T cell Engager CT-95July 10, 2024 | globenewswire.comContext Therapeutics (NASDAQ:CNTX) Stock Price Up 5.4%Context Therapeutics (NASDAQ:CNTX) Stock Price Up 5.4%July 10, 2024 | marketbeat.comContext Therapeutics Inc. (NASDAQ:CNTX) Short Interest UpdateContext Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) was the recipient of a large growth in short interest in the month of May. As of May 31st, there was short interest totalling 1,320,000 shares, a growth of 30.7% from the May 15th total of 1,010,000 shares. Currently, 2.0% of the company's stock are sold short. Based on an average trading volume of 567,900 shares, the short-interest ratio is currently 2.3 days.June 15, 2024 | marketbeat.com975,000 Shares in Context Therapeutics Inc. (NASDAQ:CNTX) Bought by Opaleye Management Inc.Opaleye Management Inc. bought a new position in Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 975,000 shares of the company's stock, valued at approximateJune 15, 2024 | marketbeat.comThe 100%+ Club: Piper Sandler's 3 Top Picks for Triple-Digit GainsMay 22, 2024 | investorplace.comPiper Sandler Initiates Coverage of Context Therapeutics (CNTX) with Overweight RecommendationMay 16, 2024 | msn.comOptimistic Outlook for Context Therapeutics’ CTIM-76 Based on Targeting Efficacy and Market PotentialMay 16, 2024 | markets.businessinsider.com Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] CNTX Media Mentions By Week CNTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CNTX News Sentiment▼-0.500.46▲Average Medical News Sentiment CNTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CNTX Articles This Week▼01▲CNTX Articles Average Week Get Context Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies UNCY News MREO News ARCT News YMAB News ZVRA News ESPR News RGNX News SLRN News MGTX News ALMS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CNTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Context Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Context Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
